Evotec & IR Pharma Ink Respiratory Discovery Pact

Under the alliance, Evotec will offer fully integrated respiratory and inflammation focused drug discovery programs, from target to nomination of preclinical development candidates.

Hamburg-based Evotec AG and UK-based IR Pharma have formed an exclusive strategic alliance to provide integrated drug discovery solutions in the field of respiratory diseases.

The alliance expands Evotec's drug discovery platform into the area of respiratory diseases through IR Pharma's expertise in in vitro and in vivo respiratory pharmacology.

Also, Evotec is now able to offer fully integrated respiratory and inflammation focused drug discovery programs, from target to nomination of preclinical development candidates.

Mario Polywka, chief operating officer at Evotec AG, said, "We are looking forward to partnering with IR Pharma and are excited abo